

Curriculum Vitae

Niels Reinmuth Professor, Dr. med.
d.o.b. December 31st, 1970, in Heidelberg, Germany

University Education

1990-1997 Studies of Medicine, Westphalian-Wilhelms-University of Münster
18.6.1997 Doctorate Medicine, Westphalian-Wilhelms-University of Münster
1.4.2010 Habilitation Internal Medicine, University of Heidelberg
Since February 2022 Adjunct Professor of Medicine, Ludwig-Maximilians-University Munich.

Scientific Career

1997-1999 Residency at the University Hospital Bergmannsheil, Bochum, Germany,
1999-2001 Postdoctoral fellowship at the Department of Cancer Biology at the UT M.D.Anderson
Cancer Center, Houston, Texas
2002-2005 Residency at the Department of Medicine/Haematology and Oncology, University of
Muenster, Germany.
2005-2010 Resident, Thoraxklinik Heidelberg, Department of Thoracic Oncology, University of
Heidelberg, Germany.
2007 Board certification for "General Medicine",
2008 Board certification for "Haematology and General Oncology"
2010 Board certification for "Pneumology"
2010-2011 Senior Physician, Resident, Thoraxklinik Heidelberg, Department of Thoracic
Oncology, University of Heidelberg, Germany.
2012-2016 Senior Physician, Lung Clinic Grosshansdorf, Department of Thoracic Oncology,
Grosshansdorf, Germany.
Since 2016 Consultant and Head of the Thoracic Oncology Department, Asklepios Lung Clinic
in Munich-Gauting, Germany.

Top-10 selected Publications

Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in
DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study.

Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen
K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y,
Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N.J Thorac Oncol. 2021 Feb 16:S1556-0864(21)01709-
3

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric
Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X,
McClelland M, Mocchi S, Jassem J, Spigel DR.N Engl J Med. 2020 Oct 1;383(14):1328-133

Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and
improves survival in mice.

Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA,
Westlin WF, Ellis LM.Cancer Res. 2003 May 1;63(9):2079-87.

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, John A, Scheele J, Heymach JV, Le X.

N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407.

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, Reznick DM, Badin FB, Cicin I, Mekan S, Patel R, Zhang E, Karumanchi D, Garassino MC.

J Clin Oncol. 2024 May 31;JCO2400733. doi: 10.1200/JCO.24.00733.

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.

Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T; POSEIDON investigators.

J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975.

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).

Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J, Califano R, Nishio M, Orlandi F, Alatorre-Alexander J, Leal T, Cheng Y, Lee JS, Lam S, McClelland M, Deng Y, Phan S, Horn L.

J Clin Oncol. 2021 Feb 20;39(6):619-630. doi: 10.1200/JCO.20.01055.

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators.

Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8.

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators.

Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F.

Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6.